Results 241 to 250 of about 273,215 (316)

Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Tacrolimus is a cornerstone immunosuppressant in transplantation medicine with a narrow therapeutic window. Drug–drug interactions with strong CYP3A4 and P‐glycoprotein modulators, such as rifampin and azole antifungals, significantly alter tacrolimus exposure and complicate therapy. Two transplant cases illustrates the impact of rifampin on tacrolimus
Jeroen P. A. Houwen   +6 more
wiley   +1 more source

Associated Factors to Nonadherence to Routine Appointments after Kidney Transplantation: The ADHERE Brazil Study. [PDF]

open access: yesClin Transplant
Karlburger RL   +8 more
europepmc   +1 more source

Renal Arterial Anatomy: Implications for Normothermic Machine Perfusion in Renal Transplantation

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Normothermic machine perfusion (NMP) is a novel technology that has shown potential in viability assessment and reconditioning of donor organs. Normothermic machine perfusion is technically more challenging in kidneys with multiple renal arteries (RAs).
Lily Mae Miller   +3 more
wiley   +1 more source

Chronic kidney disease management in patients with a failing graft: a comparative study with incident non-transplant hemodialysis patients

open access: yesRenal Failure
Ana Rita Silva   +9 more
doaj   +1 more source

Bibliometric and visual analysis of overlooked fatigue in kidney transplantation: a narrative review. [PDF]

open access: yesAnn Med Surg (Lond)
Zhu X   +10 more
europepmc   +1 more source

Ethical Issues Involved in Solid Organ Xenotransplantation

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Xenotransplantation (specifically, genetically modified pig‐to‐human transplant of organs, tissues, or cells) clinical trials are set to begin in the United States after decades of pre‐clinical studies and recent decedent and compassionate use investigations. This article provides a primer on the key ethical issues attendant with this emerging
Daniel J. Hurst   +2 more
wiley   +1 more source

CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer

open access: yesCancer Communications, EarlyView.
Abstract Background Third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show initial efficacy in EGFR‐mutated lung cancer, but residual disease persists. This study aimed to investigate cluster of differentiation 24 (CD24) as a translational immunotherapeutic target for enhancing third‐generation EGFR‐TKI efficacy.
Jiaqi Liang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy